



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 217/22, 401/04, 405/04, 417/04, 409/04, C07F 7/08, C07D 495/04, A61K 31/47 // (C07D 495/04, 333:00, 221:00)		A1	(11) International Publication Number: WO 97/38977 (43) International Publication Date: 23 October 1997 (23.10.97)
(21) International Application Number: PCT/SE97/00589 (22) International Filing Date: 9 April 1997 (09.04.97) (30) Priority Data: 960771/7 13 April 1996 (13.04.96) GB 9608678.0 26 April 1996 (26.04.96) GB 9610892.3 24 May 1996 (24.05.96) GB (71) Applicant (for all designated States except MG US): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts WD4 8DH (GB). (71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S- 151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): HAMLEY, Peter [GB/GB]; 25 Fowke Street, Rothley, Leics. LE17 7PJ (GB). MACDONALD, James [US/US]; 92 Canfield Road, Pittsford, NY 14534 (US). MATZ, James [US/US]; 60 Waterford Way, Fairport, NY 14450 (US). TINKER, Alan [GB/GB]; 97 Knightthorpe Road, Loughborough, Leics. LE11 5JR (GB).		(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU; ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: AMINOISQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI- INFLAMMATORY AGENTS			
(I)			
(57) Abstract			
Compounds of formula (I) wherein R represents (i) phenyl, benzothiazolyl or a six-membered heterocyclic aromatic ring containing 1 to 3 nitrogen atoms, which phenyl, benzo ring of the benzothiazolyl or heterocyclic aromatic ring is optionally substituted by alkyl C1 to 6, alkoxy C1 to 6, halogen, hydroxy, thioalkyl C1 to 6, benzyloxy, or a group $-(CH_2)_pNR^4R^5$; or (ii) alkyl C1 to 8, cycloalkyl C3 to 8, alkynyl C2 to 8, piperidyl, phenylalkyl C7 to 14, which alkyl, cycloalkyl, alkynyl, or piperidyl is optionally substituted by a group $-(CH_2)_pNR^4R^5$, the phenylalkyl being optionally substituted by a group $-(CH_2)_pNR^4R^5$, alkyl C1 to 6, alkoxy C1 to 6, halogen or nitro; or (iii) a five-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N or S, optionally substituted by alkyl C1 to 6, phenylalkyl C7 to 14 or halogen; or (iv) hydrogen or phenylalkynyl C7 to 14; Q represents O, NR^6 or a bond; R^1 represents hydrogen, alkyl C1 to 6, alkoxy C1 to 6, trimethylsilyl or halogen; R^2 represents hydrogen, alkyl C1 to 6 or phenyl optionally substituted by alkyl C1 to 6, alkoxy C1 to 6, halogen or hydroxy; R^3 represents hydrogen or halogen; R^4, R^5 and R^6 independently represent hydrogen or alkyl C1 to 6, or $-NR^4R^5$ together represents piperidyl, pyrrolidinyl or morpholinyl; p represents an integer 1 to 5; and A represents a thieno or benzo ring; provided that when A represents a benzo ring and Q represents O, p does not represent 1; or pharmaceutically acceptable salts, enantiomers or tautomers thereof; have been found to be useful as pharmaceuticals, especially for the treatment of inflammatory disease.			